Verteporfin: A Review of its Use in the Management of Subfoveal Choroidal Neovascularisation

Drugs

Volumn 63, Issue 22, 2003, Pages 2521-2554

  Keam, Susan J ^a   Scott, Lesley J ^a   Curran, Monique P ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Age related macular degeneration; Choroidal neovascularisation; Pathologic myopia; Pharmacodynamics; Pharmacokinetics; Photodynamic therapy; Presumed ocular histoplasmosis syndrome; Therapeutic use; Tolerability; Verteporfin

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; CYTOCHROME P450 ISOENZYME; LOW DENSITY LIPOPROTEIN RECEPTOR; PHOTOSENSITIZING AGENT; PLACEBO;

AREA UNDER THE CURVE; BACKACHE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; ELDERLY CARE; HISTOPATHOLOGY; HUMAN; INJECTION SITE; JAPAN; KIDNEY DISEASE; LIVER DISEASE; MYOPIA; OCULAR HISTOPLASMOSIS; PHARMACOECONOMICS; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; RECURRENT DISEASE; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; VISUAL DISORDER; VITREOUS HEMORRHAGE;

CUCUMBER NECROSIS VIRUS;

EID: 0242524603     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363220-00016     Document Type: Review

References (126)

1. Schmidt-Erfurth U, Kasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 2000; 45 (3): 195-214
2. Henderson BW, Dougherty TJ. How does photodynamic therapy work? Photochem Photobiol 1992; 55 (1): 145-57
3. Manyak MJ, Russo A, Smith PD, et al. Photodynamic therapy. J Clin Oncol 1988; 6 (2): 380-91
4. Roberts WG, Hasan T. Role of neovasculature and vascular permeability on the tumor retention of photodynamic agents. Cancer Res 1992; 52: 924-30
5. Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamic therapy. J Natl Cancer Inst 1998 Jun 17; 90 (12): 889-995
6. Nelson JS, Liaw L-H, Orenstein A, et al. Mechanism of tumor destruction following photodynamic therapy with hematoporphyrin derivative, chlorin and phthalocyanine. J Natl Cancer Inst 1988; 80: 1599-605
7. Schmidt-Erfurth U, Hasan T, Gragoudas E, et al. Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology 1994; 101: 1953-61
8. Schmidt-Erfurth U, Bauman MD, Gragoudas E, et al. Photodynamic therapy of experimental choroidal melanoma using lipoprotein-delivered benzoporphyrin. Ophthalmology 1994; 101: 89-99
9. Soubrane G, Bressler NM. Treatment of subfoveal choroidal neovascularisation in age related macular degeneration: focus on clinical application of verteporfin photodynamic therapy. Br J Ophthalmol 2001 Apr; 85 (4): 483-95
10. Doris N, Hart PM, Chakravarthy U, et al. Relation between macular morphology and visual function in patients with choroidal neovascularisation of age related macular degeneration. Br J Ophthalmol 2001 Feb; 85 (2): 184-8
11. Fine SL, Berger JW, Maguire MG, et al. Age-related macular degeneration. N Engl J Med 2000 Feb 17; 342 (7): 483-92
12. Mittra RA, Singerman LJ. Recent advances in the management of age-related macular degeneration. Optom Vis Sci 2002 Apr; 79 (4): 218-24
13. Lafaut BA, Bartz-Schmidt KU, Vanden Broecke C, et al. Clinicopathological correlation in exudative age related macular degeneration: histological differentiation between classic and occult choroidal neovascularisation. Br J Ophthalmol 2000 Mar; 84 (3): 239-43
14. Lafaut BA. Clinicopathologic correlation of surgically removed submacular tissue. Bull Soc Belge Ophtalmol 2000; 278: 49-53
15. Visudyne T-IND expected to enroll 4,000 AMD patients by drug approval. Pink Sheet 1999 Nov 22; 61 (47): 5-6
16. Novartis/QLT Visudyne expanded indications cover up to 250,000 patients. Pink Sheet 2001 Aug 27; 63 (35): 18
17. Ratkay LG, Waterfield JD, Hunt DWC. Photodynamic therapy in immune (non-oncological) disorders: focus on benzoporphyrin derivatives. Biodrugs 2000 Aug; 14: 127-35
18. Sickenberg M, Schmidt-Erfurth U, Miller JW, et al. A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes. Arch Ophthalmol 2000 Mar; 118 (3): 327-36
19. Scott LJ, Goa KL. Verteporfin. Drugs Aging 2000 Feb; 16 (2): 139-46
20. Pooler JP, Valenzeno DP. Dye-sensitized photodynamic inactivation of cells. Med Phys 1981; 8 (5): 614-28
21. Richter AM, Waterfield E, Jain AK, et al. In vitro evaluation of phototoxic properties of four structurally related benzoporphyrin derivatives. Photochem Photobiol 1990; 52: 495-500
22. Aveline B, Hasan T, Redmond RW. Photophysical and photosensitizing properties of benzoporphyrin derivative monoacid ring A (BPD-MA). Photochem Photobiol 1994 Mar; 59 (3): 328-35
23. Richter AM, Waterfield E, Jain AK, et al. Photosensitising potency of structural analogues of benzoporphyrin derivative (BPD) in a mouse tumour model. Br J Cancer 1991; 63: 87-93
24. Allison BA, Pritchard PH, Levy JG. Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative [published erratum appears in Br J Cancer 1995 Jan; 71: 214]. Br J Cancer 1994; 69: 833-9
25. Schmidt-Erfurth U, Hasan T, Schomacker K, et al. In vivo uptake of liposomal benzoporphyrin derivative and photothrombosis in experimental corneal neovascularization. Lasers Surg Med 1995; 17: 178-88
26. Richter AM, Waterfield E, Jain AK, et al. Liposomal delivery of a photosensitizer, benzoporphyrin derivative monoacid ring A (BPD), to tumor tissue in a mouse tumor model. Photochem Photobiol 1993; 57: 1000-6
27. Rousset N, Vonarx V, Eléouet S, et al. Cellular distribution and phototoxicity of benzoporphyrin derivative and Photofrin. Res Exp Med (Berl) 2000 Jun; 199 (6): 341-57
28. Richter AM, Kelly B, Chow J, et al. Preliminary studies on a more effective phototoxic agent than hematoporphyrin. J Natl Cancer Inst 1987; 79: 1327-32
29. Schnurrbusch UE, Welt K, Horn L-C, et al. Histological findings of surgically excised choroidal neovascular membranes after photodynamic therapy. Br J Ophthalmol 2001 Sep; 85 (9): 1086-91
30. Ghazi NG, Jabbour NM, De La Cruz ZC, et al. Clinicopathologic studies of age-related macular degeneration with classic subfoveal choroidal neovascularization treated with photodynamic therapy. Retina 2001; 21 (5): 478-86
31. Schmidt-Erfurth U, Laqua H, Schlotzer-Schrehard U, et al. Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol 2002 Jun; 120 (6): 835-44
32. Schlötzer-Schrehardt U, Viestenz A, Naumann GOH, et al. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol 2002 Sep; 240 (9): 748-57
33. Michels S, Schmidt-Erfurth U. Sequence of early vascular events after photodynamic therapy. Invest Ophthalmol Vis Sci 2003 May; 44 (5): 2147-54
34. Miller JW, Schmidt-Erfurth U, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization by age-related macular degeneration: results of a single treatment in a phase I and 2 study. Arch Ophthalmol 1999; 117: 1161-73
35. Schmidt-Erfurth U, Miller J, Sickenberg M, et al. Photodynamic therapy of subfoveal choroidal neovascularization: clinical and angiographic examples. Graefes Arch Clin Exp Ophthalmol 1998; 236: 365-74
36. Schmidt-Erfurth U, Miller JW, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatment in a phase 1 and 2 study. Arch Ophthalmol 1999; 117: 1177-87
37. Chen JC, Marinier JA, Kergoat H, et al. Choroidal blood flow in verteporfin treatment of age related macular degeneration [abstract]. Invest Ophthalmol Vis Sci 2002; 43: E586
38. Houle J-M, Strong HA. Duration of skin photosensitivity and incidence of photosensitivity reactions after administration of verteporfin. Retina 2002 Dec; 22 (6): 691-7
39. Kaiser PK. Photodynamic therapy with verteporfin for choroidal neovascularization. Todays Ther Trends 2000; 18 (4): 313-26
40. Schmidt-Erfurth U, Michels S, Barbazetto I, et al. Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci 2002 Mar; 43 (3): 830-41
41. Houle J-M, Strong A. Clinical pharmacokinetics of verteporfin. J Clin Pharmacol 2002 May; 42 (5): 547-57
42. Haimovici R, Kramer M, Miller JW, et al. Localization of lipoprotein-delivered benzoporphyrin derivative in the rabbit eye. Curr Eye Res 1997 Feb; 16 (2): 83-90
43. Novartis. Prescribing information: Visudyne (verteporfin for injection) [online]. Available from URL; http:// www.visudyne.com [Accessed 2003 May 12]
44. Treatment of Age-related Macular Degeneration with Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one year results of 2 randomized clinical trials - TAP Report 1. Arch Ophthalmol 1999; 117: 1329-45
45. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP Report 2. Arch Ophthalmol 2001 Feb; 119 (2): 198-207
46. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes -TAP Report no. 3. Arch Ophthalmol 2002 Nov; 120 (11): 1443-54
47. Rubin GS, Bressler NM, and the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Effects of verteporfin therapy on contrast on sensitivity: results From the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Investigation - TAP Report no. 4. Retina 2002 Oct; 22 (5): 536-44
48. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001 May; 131: 541-60
49. Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: 1-year results of a randomized clinical trial - VIP report no. 1. Ophthalmology 2001 May; 108 (5): 841-52
50. Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial - VIP Report no. 3. Ophthalmology 2003; 110: 667-73
51. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials - TAP Report no. 5. Arch Ophthalmol 2002 Oct; 120 (10): 1307-14
52. Singerman LJ. Two-year results of an open-label extension of the TAP Investigation evaluating verteporfin therapy for subfoveal CNV due to AMD. TAP Study Group [abstract]. Retina 2002 Congress; 2002 Sep 28-Oct 2; San Francisco
53. Kaiser PK, and TAP Study group. Five-year results of verteporfin therapy for subfoveal CNV due to AMD: third year of an open-label extension of the TAP Investigation [abstract]. Invest Ophthalmol Vis Sci 2003; 44: E1099
54. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin In Photodynamic Therapy (VIP) Study Groups. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP Report No. 1. Am J Ophthalmol 2003 Sep; 136 (3): 407-18
55. Montero JA, Ruiz-Moreno JM. Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation. Br J Ophthalmol 2003 Feb; 87 (2): 173-6
56. Saperstein DA, Rosenfeld PJ, Bressler NM, et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: one-year results of an uncontrolled, prospective case series. Ophthalmology 2002 Aug; 109 (8): 1499-505
57. Saperstein DA. Effects over two years of verteporfin therapy on choroidal neovascularization secondary to the ocular histoplasmosis syndrome (VOH study). VOH Study Group [abstract]. Invest Ophthalmol Vis Sci 2002 May; 43: E982
58. Busquets MA, Shah GK, Wickens J, et al. Ocular photodynamic therapy with verteporfin for choroidal neovascularization secondary to ocular histoplasmosis syndrome. Retina 2003 Jun; 23 (3): 299-306
59. Japanese Age-related Macular Degeneration Trial (JAT) Study Group. Japanese age-related macular degeneration trial (JAT): one-year results of photodynamic therapy in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol 2003; available at http://www.ajo.com [Accessed 19 Sept 2003]
60. Potter MJ, Szabo SM, Hao Y. Twelve month clinical outcomes following treatment of subfoveal choroidal neovascularization in age-related macular degeneration using photodynamic therapy with verteporfin (Visudyne). Invest Ophthalmol Vis Sci 2003; 44: E-1772
61. Data on file. Vancouver (BC): QLT Inc., 2003 Sep
62. Sharma S. Update in retina: photodynamic therapy for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Can J Ophthalmol 2001 Feb; 36 (1): 7-10
63. Wormald R, Evans J, Smeeth L. Photodynamic therapy for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews. Available in the Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 3. Oxford: Update Software, 2003: CD002030
64. QLT Inc. New clinical data confirm role of visudyne (verteporfin) therapy as standard of care in choroidal neovascularization (CNV) due to age-related macular degeneration [media release]. 2003 Sep 18
65. Schmidt-Erfurth UM, Michels S. Changes in confocal indocyanine green angiography through two years after photodynamic therapy with verteporfin. Ophthalmology 2003 Jul; 110 (7): 1306-14
66. Sharma S, Hollands H, Brown GC, et al. Improvement in quality of life from photodynamic therapy: a Canadian perspective. Can J Ophthalmol 2001; 36: 332-8
67. QLT Inc. Commercial: Visudyne - approval status [online]. Available from URL: http://www.qtlinc.com [Accessed 2003 Sep 19]
68. Bressler NM. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2002 Jan; 133 (1): 168-9
69. Smith DH, Drummond M, Fenn P. Modelling the log-term benefits of photodynamic therapy (PDT) with verteporfin for age-related macular degeneration (AMD) Discussion paper 187 [online]. Available from URL: http://www.york.ac.uk/ inst/che/DP187full.pdf [Accessed 2003 Apr 7]
70. Smith DH, Fenn P, Drummond M. Cost effectiveness of photodynamic therapy (PDT) with verteporfin in the UK [abstract no. PES6]. Value Health 2002; 5: 247
71. Sharma S, Brown GC, Brown MB, et al. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2001; 108: 2051-9
72. Beaumont P, Singerman LJ, Lees M, et al. Economic evaluation of photodynamic therapy with verteporfin for predominantly classic subfoveal CNV secondary to AMD [abstract]. Retina 2002 Congress; 2002 Sep 28-Oct 2; San Francisco
73. Lees M, Davey PJ, Price N, et al. Economic evaluation of photodynamic therapy with verteporfin for small subfoveal CNV lesions: the case of Australia [abstract no. PES6]. Value Health 2003; 6 (3): 239
74. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992 Feb 15; 146: 473-81
75. Borodoker N, Spaide RF, Maranan L, et al. Verteporfin infusion-associated pain. Am J Ophthalmology 2002; 133: 211-4
76. Spaide RF, Maranan L. Neutrophil margination as a possible mechanism for verteporfin infusion-associated pain. Am J Ophthalmol 2003 Apr; 135 (4): 549-50
77. Noffke AS, Jampol LM, Weinberg DV, et al. A potentially life-threatening adverse reaction to verteporfin [letter]. Arch Ophthalmol 2001 Jan; 119 (1): 143
78. Gelisken F, Inhoffen W, Partsch M, et al. Retinal pigment epithelial tear after photodynamic therapy for choroidal neovascularization. Am J Ophthalmol 2001 Apr; 131 (4): 518-20
79. Srivastava SK, Sternberg Jr P. Retinal pigment epithelial tear weeks following photodynamic therapy with verteporfin for choroidal neovascularization secondary to pathological myopia. Retina 2002 Oct; 22 (5): 669-71
80. Cahill MT, Smith BT, Fekrat S. Adverse reaction characterized by chest pain, shortness of breath, and syncope associated with verteporfin (Visudyne). Am J Ophthalmol 2002 Aug; 134 (2): 281-2
81. The European Agency for the Evaluation of Medicinal Products (EMEA). Summary of product characteristics: Visudyne [online]. Available from URL: http://www.eudra.org/humandocs/ Humans/EPAR/Visudyne/Visudyne.htm [Accessed 2003 May 12]
82. Visudyne infusion. Pharm J 2000 Aug 5; 265: 213
83. Schmidt-Erfurth U, Laqua H. Photodynamische therapie: Empfehlungen für Indikation und Behandlung. Der Ophthalmologe 2001; 98: 216-30
84. Novartis Pharmaceutical Canada Inc. Visudyne prescribing information [online]. Available from URL: http:// www.pharma.ca.novartis.com/e/products/ visudyne.shtml [Accessed 2003 Sep 19]
85. Novartis Pharmaceuticals Australia Pty Ltd. Visudyne (verteporfin) prescribing information [online]. Available from URL: http://www.novartis.com. au/healthcare_professionals.html [Accessed 2003 Sep 19]
86. McMillan TA, Lashkari K. Ocular histoplasmosis. Int Ophthalmol Clin 1996 Summer; 36 (3): 179-86
87. Miller DG, Singerman LJ. Natural history of choroidal vascularization in high myopia: retina and vitreous disorders. Curr Opin Ophthalmol 2001 Jun; 12 (3): 222-4
88. Ferns III FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984; 102: 1640-2
89. Ciulla TA, Piper HC, Xiao M, et al. Presumed ocular histoplasmosis syndrome: update on epidemiology, pathogenesis, and photodynamic, antiangiogenic, and surgical therapies. Curr Opin Ophthalmol 2001 Dec; 12 (6): 442-9
90. Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol 1988; 32 (6): 375-413
91. la Cour M, Kiilgaard JF, Nissen MH. Age-related macular degeneration: epidemiology and optimal treatment. Drugs Aging 2002; 19 (2): 101-33
92. Tano Y. LIX Edward Jackson Memorial Lecture. Pathologic myopia: where are we now? Am J Ophthalmol 2002 Nov; 134 (5): 645-60
93. Klein R, Klein BE, Linton KLP. Prevalence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 1992; 99: 933-43
94. Thylefors B, Négrel A-D, Pararajasegaram R, et al. Global data on blindness. Bull World Health Organ 1995; 73 (1): 115-21
95. Evans J. Causes of blindness and partial sight in England and Wales 1990-1991. London: HMSO, 1995; 57: 1-29
96. Vingerling JR, Dielemans I, Hofman A, et al. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology 1995; 102: 205-10
97. Mitchell P, Smith W, Attebo K, et al. Prevalence of age-related maculopathy in Australia: the Blue Mountains Eye Study. Ophthalmology 1995; 102: 1450-60
98. Vingerling JR, Klaver CC, Hofman A, et al. Epidemiology of age-related maculopathy. Epidemiol Rev 1995; 17 (2): 347-60
99. Bressler SB, Maguire MG, Bressler NM, et al. Relationship of drusen and abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular degeneration. Arch Ophthalmol 1990; 108: 1442-7
100. Strahlman ER, Fine SL, Hillis A. The second eye of patients with senile macular degeneration. Arch Ophthalmol 1983; 101 (1191-1193)
101. Takashima T, Yokoyama T, Futagami S, et al. The quality of life in patients with pathologic myopia. Jpn J Ophthalmol 2001 Jan-2001 28; 45 (1): 84-92
102. Secrétan M, Kuhn D, Soubrane G, et al. Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment. Eur J Ophthalmol 1997 Oct-1997 31; 7 (4): 307-16
103. Avila MP, Weiter JJ, Jalkh AE, et al. Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 1984; 91: 1573-81
104. Hampton GR, Kohen D, Bird AC. Visual prognosis of disciform degeneration in myopia. Ophthalmology 1983; 90: 923-6
105. Suttorp-Schulten MS. The etiology of the presumed ocular histoplasmosis syndrome. Ocul Immunol Inflamm 1997 Mar; 5 (1): 71-2
106. Berger AS, Conway M, Del Priore LV, et al. Submacular surgery for subfoveal choroidal neovascular membranes in patients with presumed ocular histoplasmosis. Arch Ophthalmol 1997 Aug; 115 (8): 991-6
107. Cummings HL, Rehmar AJ, Wood WJ, et al. Long-term results of laser treatment in the ocular histoplasmosis syndrome. Arch Ophthalmol 1995 Apr; 113 (4): 465-8
108. Atebara NH, Thomas MA, Holekamp NM, et al. Surgical removal of extensive peripapillary choroidal neovascularization associated with presumed ocular histoplasmosis syndrome. Ophthalmology 1998 Sep; 105 (9): 1598-605
109. Baskin MA, Jampol LM, Huamonte FU, et al. Macular lesions in Blacks with the presumed ocular histoplasmosis syndrome. Am J Ophthalmol 1980; 89: 77-83
110. Macular Photocoagulation Study Group. Five-year follow-up of fellow eyes of individuals with ocular histoplasmosis and unilateral extrafoveal or juxtafoveal choroidal neovascularization. Arch Ophthalmol 1996 Jun; 114 (6): 677-88
111. Macular Photocoagulation Study Group. Five-year follow-up of fellow eyes of patients with age-related macular degeneration and unilateral extrafoveal choroidal neovascularization. Arch Ophthalmol 1993; 111: 1189-99
112. Lewis ML, van Newkirk MR, Gass JDM. Follow-up study of presumed ocular histoplasmosis syndrome. Ophthalmology 1980; 87: 390-9
113. Macular Photocoagulation Study Group. Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Arch Ophthalmol 1997 Jun; 115 (6): 741-7
114. Schmidt-Erfurth U. Progression of age-related macular degeneration in fellow eyes of patients enrolled in the TAP Investigation and the VIP Trial. TAP Study Group and the VIP Study Group [abstract]. Retina 2002 Congress; Sept 28-Oct 2; San Francisco
115. Stokkermans TJW. Treatment of age-related macular degeneration. Clinical Eye & Vision Care 2000; 12 (1-2): 15-35
116. Freund KB, Yannuzzi LA, Sorenson JA. Age-related macular degeneration and choroidal neovascularization. Am J Ophthalmol 1993; 115: 786-91
117. Verteporfin Roundtable 2000 and 2001 Participants, Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Principal Investigators, and Verteporfin in Photodynamic Therapy (VIP) Study Group Principal Investigators. Guidelines for using verteporfin (Visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina 2002; 22 (1): 6-18
118. American Academy of Ophthalmology. Summary of benchmarks for preferred practice patterns [online]. Available from URL: http://www.aao.org [Accessed 2003 Sep 23]
119. Royal College of Ophthalmologists. Guidelines for photodynamic therapy [online]. Available from URL: http:// www.rcopahth.ac.uk/publications/ guidelines/ [Accessed 2002 Mar 1]
120. National Institute for Clinical Excellence. Guidance on the use of photodynamic therapy for age-related macular degeneration [online]. Available from URL: http://www.nice.org.uk [Accessed 2003 Sep 24]
121. Lees MJ, Aldridge GJ, Davey PJ, et al. Economic evaluation of photodynamic therapy with verteporfin. Ophthalmology 2003 Apr; 110 (4): 626-7
122. Suner I, Cruz-Villegas V, Hnik P, et al. Verteporfin therapy with delayed light application of occult choroidal neovascularization (CNV) in age-related macular degeneration (AMD) [abstract]. Retina 2002 Congress; 2002 Sep 28-Oct 2; San Francisco
123. Schmidt-Erfurth U, Michels S, Kusserow C. A comparison of shorter treatment intervals versus the standard regimen in photodynamic therapy: an interims-analysis after 6 months [abstract]. Invest Ophthalmol Vis Sci 2003; 44: E1102
124. Novartis Ophthalmics. Current clinical trials [online]. Available from URL: http://visudyne.com [Accessed 2001 Nov 2]
125. Bressler NM, Rosenfeld PJ, Lim JI, et al. A phase II placebo-controlled, double-masked, randomized trial - verteporfin in minimally classic CNV due to AMD (VIM) [abstract]. Invest Ophthalmol Vis Sci 2003; 44: E1100
126. Ocular surgery news 12/15/02: results stable in 3-year extension of VIP trial for pathologic myopia. 8th Annual Symposium on Cataract, Glaucoma and Refractive surgery, Florence [media release]. 2002 15 Dec